Frederick Locke

42PUBLICATIONS
283CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsiesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Jul 17, 2026
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

|May 11, 2026
Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

|Nov 13, 2025
Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.

Caron A Jacobson, Jason R Westin, David B Miklos

|Jul 07, 2025
Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.

Assia Hijazi, Frederick L Locke, Nathalie Scholler

|May 22, 2025
Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies.

Benjamin Diamond, Dhanvantri Chahar, Michael D Jain

|Apr 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma.

Khushali Jhaveri, Ram Thapa, Dalia Ercan

Pageof 7

Frequent Collaborators

16 joint publications

Michael Jain

10 joint publications

Olalekan Oluwole

9 joint publications

David B Miklos

8 joint publications

Taiga Nishihori